MOSBRI: A European Research Infrastructure for Molecular Biophysics

On the 1st of July 2021 the molecular-scale biophysics EU programme **MOSBRI** commences operation.



Apply for access to laboratories of excellence

Applications for transnational access are now being accepted via our proposal submission system at https://www.mosbri.eu/apply-for-tna/.

One of the principal activities of the MOSBRI project is to offer free-of-charge transnational access for researchers in academia and industry. MOSBRI offers access to laboratories of excellence working on the architecture, dynamics, and interactions of the giant molecules of life (proteins, DNA, RNA, polysaccharides, lipids) at the crucial intermediate level between atomic-resolution structural descriptions and cellular-scale observations. This enables invaluable insights into the complex behaviour of macromolecular assemblies.

Through our networking activities, MOSBRI will also disseminate its know-how through training schools (https://www.mosbri.eu/training/) and annual scientific conferences.

ProLinc 7
Linköping

AU-SRCD
Aarhusi 24

MALVERN 14
Malvern •
ISMB-BIOPHYSX •
London
Pasteur-PFBMI •
Paris

AFFINImeter
Santiago de
Compostela • 15

EPR-MRS • IO
Marseille

BIFI-LACRIMA • 13
Zaragoza

ProLinc 7
Linköping

RUG-BP 6 • EMBL-SPC
Groningen Hamburg
ULB
• 3
Wob-IBT • 11
Vestec/Prague

• NIC
Ljubljana
Genoa

1 • DSB-UROM
Rome

MOSBRI's joint research activities aim to enhance the

transnational access offered, define and validate standards and best practices in quantitative analysis of biomolecular behaviour, as well as develop data formats, data processing procedures and databases for biophysical data archiving and retrieval.

MOSBRI is a consortium of 13 academic centres of excellence and 2 industrial partners from 11 different European countries, coordinated by Institut Pasteur (Paris, France). MOSBRI aims to address the pressing need for a truly integrated and multi-methodological taskforce, combining the best up-to-date instrumentation and the best expertise available in Europe, to the benefit of all researchers in the fields of biomedicine, biotechnology, biomaterials and beyond, from both academia and industry.